Comparison
Semax vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
80714-61-0
2023788-19-2
Molecular weight
813.92 g/mol
4813 g/mol
Half-life
0.3 h
116 h
Sequence
Met-Glu-His-Phe-Pro-Gly-ProYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
3
of which in humans
2
3
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
1
2